RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
HLB Therapeutics Co Stock

HLB Therapeutics Co Equity 2024

HLB Therapeutics Co Equity

160.47 B KRW

Ticker

115450.KQ

ISIN

KR7115450009

In 2024, HLB Therapeutics Co's equity was 160.47 B KRW, a 37.49% increase from the 116.71 B KRW equity in the previous year.

HLB Therapeutics Co Aktienanalyse

What does HLB Therapeutics Co do?

HLB Therapeutics Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing HLB Therapeutics Co's Equity

HLB Therapeutics Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding HLB Therapeutics Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating HLB Therapeutics Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

HLB Therapeutics Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in HLB Therapeutics Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about HLB Therapeutics Co stock

What is the equity of HLB Therapeutics Co this year?

HLB Therapeutics Co has equity of 160.47 B KRW this year.

What was the equity of HLB Therapeutics Co compared to the previous year?

The equity of HLB Therapeutics Co has increased/decreased by 37.49% increased compared to the previous year.

What impact does a high equity have on investors of HLB Therapeutics Co?

A high equity is advantageous for investors of HLB Therapeutics Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of HLB Therapeutics Co?

A low equity can be a risk for investors of HLB Therapeutics Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of HLB Therapeutics Co affect the company?

An increase in equity of HLB Therapeutics Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of HLB Therapeutics Co affect the company?

A reduction in equity of HLB Therapeutics Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of HLB Therapeutics Co?

Some factors that can affect the equity of HLB Therapeutics Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of HLB Therapeutics Co so important for investors?

The equity of HLB Therapeutics Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can HLB Therapeutics Co take to change the equity?

To change equity, HLB Therapeutics Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does HLB Therapeutics Co pay?

Over the past 12 months, HLB Therapeutics Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Therapeutics Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of HLB Therapeutics Co?

The current dividend yield of HLB Therapeutics Co is .

When does HLB Therapeutics Co pay dividends?

HLB Therapeutics Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of HLB Therapeutics Co?

HLB Therapeutics Co paid dividends every year for the past 0 years.

What is the dividend of HLB Therapeutics Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is HLB Therapeutics Co located?

HLB Therapeutics Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLB Therapeutics Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLB Therapeutics Co from 10/8/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.

When did HLB Therapeutics Co pay the last dividend?

The last dividend was paid out on 10/8/2024.

What was the dividend of HLB Therapeutics Co in the year 2023?

In the year 2023, HLB Therapeutics Co distributed 0 KRW as dividends.

In which currency does HLB Therapeutics Co pay out the dividend?

The dividends of HLB Therapeutics Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von HLB Therapeutics Co

Our stock analysis for HLB Therapeutics Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Therapeutics Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.